Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer

Peter Langenstroer, Brandon Kramer, Bradley Cutting, Christopher Amling, Thomas Poultan, Raymond Lance, J. Brantley Thrasher

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: Luteinizing hormone releasing hormone (LHRH) agonist therapy for advanced prostate cancer can manifest significant side effects affecting quality of life, most notably hot flashes. This study evaluated the effectiveness of parenteral medroxyprogesterone acetate (MPA) in reducing the frequency and severity of these hot flashes. Materials and Methods: A multi-institutional retrospective review of hot flashes from LHRH therapy for prostate cancer was conducted. The hot flashes were quantified and the severity was graded (3-point analogue scale) before and after treatment with MPA. Two doses of MPA (400 or 150 mg intramuscularly) were administered. Statistical analysis (Student's t test) evaluated the quantity of hot flashes, the quality of hot flashes, and dose effectiveness. Results: A total of 48 men (40 at 400 mg, 8 at 150 mg) with a mean age of 71.4 years (range 54 to 87) from 3 institutions were evaluated. There were 91% with symptomatic improvement with MPA, and half (46%) had a complete response defined as total elimination of hot flashes. The median number of the hot flashes per day decreased from 4 to 1 and the median severity score decreased from 2 to 1 (p

Original languageEnglish (US)
Pages (from-to)642-645
Number of pages4
JournalJournal of Urology
Volume174
Issue number2
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Medroxyprogesterone
Hot Flashes
Gonadotropin-Releasing Hormone
Prostatic Neoplasms
Medroxyprogesterone Acetate
Therapeutics
Quality of Life
Students

Keywords

  • Goserelin
  • Hot flashes
  • Medroxyprogesterone 17-acetate
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. / Langenstroer, Peter; Kramer, Brandon; Cutting, Bradley; Amling, Christopher; Poultan, Thomas; Lance, Raymond; Thrasher, J. Brantley.

In: Journal of Urology, Vol. 174, No. 2, 08.2005, p. 642-645.

Research output: Contribution to journalArticle

Langenstroer, Peter ; Kramer, Brandon ; Cutting, Bradley ; Amling, Christopher ; Poultan, Thomas ; Lance, Raymond ; Thrasher, J. Brantley. / Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. In: Journal of Urology. 2005 ; Vol. 174, No. 2. pp. 642-645.
@article{4ee129c556f34fa18d36c8050381711d,
title = "Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer",
abstract = "Purpose: Luteinizing hormone releasing hormone (LHRH) agonist therapy for advanced prostate cancer can manifest significant side effects affecting quality of life, most notably hot flashes. This study evaluated the effectiveness of parenteral medroxyprogesterone acetate (MPA) in reducing the frequency and severity of these hot flashes. Materials and Methods: A multi-institutional retrospective review of hot flashes from LHRH therapy for prostate cancer was conducted. The hot flashes were quantified and the severity was graded (3-point analogue scale) before and after treatment with MPA. Two doses of MPA (400 or 150 mg intramuscularly) were administered. Statistical analysis (Student's t test) evaluated the quantity of hot flashes, the quality of hot flashes, and dose effectiveness. Results: A total of 48 men (40 at 400 mg, 8 at 150 mg) with a mean age of 71.4 years (range 54 to 87) from 3 institutions were evaluated. There were 91{\%} with symptomatic improvement with MPA, and half (46{\%}) had a complete response defined as total elimination of hot flashes. The median number of the hot flashes per day decreased from 4 to 1 and the median severity score decreased from 2 to 1 (p",
keywords = "Goserelin, Hot flashes, Medroxyprogesterone 17-acetate, Prostatic neoplasms",
author = "Peter Langenstroer and Brandon Kramer and Bradley Cutting and Christopher Amling and Thomas Poultan and Raymond Lance and Thrasher, {J. Brantley}",
year = "2005",
month = "8",
doi = "10.1097/01.ju.0000165570.28635.4b",
language = "English (US)",
volume = "174",
pages = "642--645",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer

AU - Langenstroer, Peter

AU - Kramer, Brandon

AU - Cutting, Bradley

AU - Amling, Christopher

AU - Poultan, Thomas

AU - Lance, Raymond

AU - Thrasher, J. Brantley

PY - 2005/8

Y1 - 2005/8

N2 - Purpose: Luteinizing hormone releasing hormone (LHRH) agonist therapy for advanced prostate cancer can manifest significant side effects affecting quality of life, most notably hot flashes. This study evaluated the effectiveness of parenteral medroxyprogesterone acetate (MPA) in reducing the frequency and severity of these hot flashes. Materials and Methods: A multi-institutional retrospective review of hot flashes from LHRH therapy for prostate cancer was conducted. The hot flashes were quantified and the severity was graded (3-point analogue scale) before and after treatment with MPA. Two doses of MPA (400 or 150 mg intramuscularly) were administered. Statistical analysis (Student's t test) evaluated the quantity of hot flashes, the quality of hot flashes, and dose effectiveness. Results: A total of 48 men (40 at 400 mg, 8 at 150 mg) with a mean age of 71.4 years (range 54 to 87) from 3 institutions were evaluated. There were 91% with symptomatic improvement with MPA, and half (46%) had a complete response defined as total elimination of hot flashes. The median number of the hot flashes per day decreased from 4 to 1 and the median severity score decreased from 2 to 1 (p

AB - Purpose: Luteinizing hormone releasing hormone (LHRH) agonist therapy for advanced prostate cancer can manifest significant side effects affecting quality of life, most notably hot flashes. This study evaluated the effectiveness of parenteral medroxyprogesterone acetate (MPA) in reducing the frequency and severity of these hot flashes. Materials and Methods: A multi-institutional retrospective review of hot flashes from LHRH therapy for prostate cancer was conducted. The hot flashes were quantified and the severity was graded (3-point analogue scale) before and after treatment with MPA. Two doses of MPA (400 or 150 mg intramuscularly) were administered. Statistical analysis (Student's t test) evaluated the quantity of hot flashes, the quality of hot flashes, and dose effectiveness. Results: A total of 48 men (40 at 400 mg, 8 at 150 mg) with a mean age of 71.4 years (range 54 to 87) from 3 institutions were evaluated. There were 91% with symptomatic improvement with MPA, and half (46%) had a complete response defined as total elimination of hot flashes. The median number of the hot flashes per day decreased from 4 to 1 and the median severity score decreased from 2 to 1 (p

KW - Goserelin

KW - Hot flashes

KW - Medroxyprogesterone 17-acetate

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=22144496466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144496466&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000165570.28635.4b

DO - 10.1097/01.ju.0000165570.28635.4b

M3 - Article

C2 - 16006929

AN - SCOPUS:22144496466

VL - 174

SP - 642

EP - 645

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -